u/Avish_Golakiya · 3h ago7 prior · awaiting results
10 penny biotechs I'm watching and slowly adding for September 2026, and the one I got wrong in August.
ARCHER II in geographic atrophy aims to show prevention of 15-letter vision loss in 630+ patients—a higher bar than approved GA drugs that only slow lesion growth. The topline window is 2H 2026 with only 12.5 months of runway, making it a binary bet with extreme implied volatility (±96%).
Now $4.8716m ago